A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer

被引：0
|
作者：
Chen, T. W-W
Yeh, D-C
Chao, T-Y
Lin, C-H
Chow, L. W-C
Hsieh, Y-Y
Huang, S-M
Cheng, A-L
Huang, C-S
Lu, Y-S
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Taichung Vet Gen Hosp, Taichung, Taiwan
[3] Taipei Med Univ, Div Hematol & Oncol, Shuang Ho Hosp, New Taipei, Taiwan
[4] UNIMED Med Inst, Comprehens Ctr Breast Dis, Wan Chai, Hong Kong, Peoples R China
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-14-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-23
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
    Chen, Tom Wei-Wu
    Yeh, Dah-Cherng
    Chao, Tsu-Yi
    Lin, Ching-Hung
    Chow, Louis Wing-Cheong
    Chang, Dwan-Ying
    Hsieh, Yao-Yu
    Huang, Shu-Min
    Cheng, Ann-Lii
    Lu, Yen-Shen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (03) : 242 - 247
  • [2] Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment
    Sim, S. H.
    Park, I. H.
    Jung, K. H.
    Kim, S-B
    Ahn, J-H
    Lee, K-H
    Im, S-A
    Im, Y-H
    Park, Y. H.
    Sohn, J. H.
    Kim, Y. J.
    Lee, S.
    Kim, H-J
    Chae, Y. S.
    Park, K-H
    Nam, B-H
    Lee, K. S.
    Ro, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Barr, J. A.
    Sharma, P.
    Fabian, C. J.
    Yeh, H.
    Baccaray, S.
    Springer, M.
    Khan, Q. J.
    CANCER RESEARCH, 2016, 76
  • [4] A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Rooney, Anthony
    Sharma, Priyanka
    O'Dea, Anne P.
    Nye, Lauren
    Elia, Manana
    He, Jianghua
    Fabian, Carol
    Khan, Qamar
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial
    Saip, P.
    Eralp, Y.
    Sen, F.
    Karaca, H.
    Ozkan, M.
    Cetin, B.
    Benekli, M.
    Kucukoner, M.
    Isikdogan, A.
    Un, O.
    Basaran, G.
    Onur, H.
    BREAST, 2013, 22 (05): : 628 - 633
  • [6] Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
    E Brain
    N Isambert
    F Dalenc
    V Diéras
    J Bonneterre
    K Rezai
    M Jimenez
    F Mefti-Lacheraf
    E Cottura
    P Tresca
    L Vanlemmens
    C Mahier-Aït Oukhatar
    F Lokiec
    P Fumoleau
    British Journal of Cancer, 2012, 106 : 673 - 677
  • [7] Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
    Brain, E.
    Isambert, N.
    Dalenc, F.
    Dieras, V.
    Bonneterre, J.
    Rezai, K.
    Jimenez, M.
    Mefti-Lacheraf, F.
    Cottura, E.
    Tresca, P.
    Vanlemmens, L.
    Oukhatar, C. Mahier-Ait
    Lokiec, F.
    Fumoleau, P.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 673 - 677
  • [8] Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
    Chew, Helen Kent
    Schwartzberg, Lee
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James
    DeSilvio, Michelle
    Mahoney, Janine
    SPRINGERPLUS, 2014, 3
  • [9] Phase II Study of Neratinib and Trastuzumab plus -oral Vinorelbine in previously treated metastatic Her2 positive Breast Cancer
    Balic, M.
    Posch, F.
    Bartsch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [10] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
    Kalinsky, Kevin
    Chi, Dow-Chung
    Lee, Shing
    Tiersten, Amy
    Makower, Della
    Chuang, Ellen
    Crew, Katherine D.
    Hershman, Dawn L.
    Silva, Jose
    Califano, Andrea
    Maurer, Matthew
    CANCER RESEARCH, 2015, 75
12345